Recombinant Neisseria Meningitidis Group B Nhba Fusion Protein Produced In E. Coli Cells By Recombinant Dna Technology Adsorbed On Aluminium Hydroxide, Recombinant Neisseria Meningitidis Group B Nada Protein Produced In E. Coli Cells By Recombinant Dna Technology Adsorbed On Aluminium Hydroxide, Recombinant Neisseria Meningitidis Group B Fhbp Fusion Protein Produced In E. Coli Cells By Recombinant Dna Technology Adsorbed On Aluminium Hydroxide, Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide

• A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of IM-101 in Adult Participants with Generalized Myasthenia Gr… Pending
  2025-522406-20-00 Phase I/II 4 countries Immunabs Inc.
• A Phase 2 study of DNTH103 in patients with Generalized Myasthenia Gravis Recruiting
  2024-512865-15-00 Phase II 9 countries Dianthus Therapeutics Inc.
• An investigator-initiated, single-center academic study in healthy transgender and cisgender persons aged between 18 and 50 years to investi… Recruiting
  2024-515599-11-00 Phase IV 1 country Universiteit Gent
• Safety and immunogenicity of an investigational Pentavalent Meningococcal ABCYW vaccine against meningococcal disease in children, toddlers,… Ended
  2023-510465-10-00 Phase II 6 countries Sanofi Pasteur Inc.
• Meningococcal B vaccine in patients with asplenia Ended
  2023-508192-36-00 Phase II 1 country Medical University of Vienna
• A study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoprolifer… Ended
  2023-504625-39-00 Phase III 8 countries Apellis Pharmaceuticals Inc.
• SPLEMENGO - Multicenter, randomized, phase III, trial assessing the immunogenicity and safety of three meningococal B vaccine strategies amo… Ended
  2024-513649-35-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• A Phase 3 study to assess the immune response and safety of rMenB+OMV NZ in primed healthy participants (10 to 20 years old) Ended
  2024-519549-31-00 Phase III 3 countries GlaxoSmithKline Biologicals
• MENACWY=MEN7B-003 Ended
  2023-506449-40-00 Phase I/II 3 countries GlaxoSmithKline Biologicals
• Proof of concept study to assess the efficacy and safety of Danicopan (factor D inhibitor) in adult patients with chronic spontaneous urtica… Ended
  2024-512386-14-00 Phase II 1 country Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

Showing 1–10 of 10 trials